Drug Approval | August 22, 2022
USFDA grants emergency use authorization for Novavax COVID-19 vaccine
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets
DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs i
The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial
The estimated capex is to the tune of Rs. 140 crore to be funded through debt and internal accrual
QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms
The vaccine has been developed by the National Equine Research Center, Hisar (Haryana) in collaboration with the Indian Veterinary Research Institute, Izzatnagar (Bareilly)
The Sri Sathya Sai Sanjeevani Super Speciality Hospital in Batticaloa will begin its operations by conducting free paediatric cardiac care surgeries and interventions in the next few days
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
Subscribe To Our Newsletter & Stay Updated
